[1] Moghal N, Sternberg PW.  Multiple positive and negative regulators of signaling by the EGR-receptor[J]. Curr Opin Cell Biol, 1999, 11(2): 190-196.   doi: 10.1016/S0955-0674(99)80025-8
[2] Capdevila J, Elez E, Maearulla T, et al.  Anti-epidermalgrowth factor receptor monoclonal antibodies in cancer treatment[J]. Cancer Treat Rev, 2009, 35(4): 354-363.   doi: 10.1016/j.ctrv.2009.02.001
[3] Casanova ML, Larcher F, Casanova B, et al.  A critical role for rasmediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis[J]. Cancer Res, 2002, 62(12): 3402-3407.
[4] Sasaki T, Kitadai Y, Nakamura T, et al.  Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice[J]. Neopla-sia, 2007, 9(12): 1066-1077.   doi: 10.1593/neo.07667
[5] Galizia G, Lieto E, Ferraraccio F, et al.  Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery[J]. Ann Surg Oncol, 2006, 13(6): 823-835.
[6] Varella-Garcia M, Diebold J, Eberhard DA, et al.  EGFR fluorescence in situ hybridisation assay: guidelines for application tononsmall-cell lung cancer[J]. J Clin Pathol, 2009, 62(11): 970-977.   doi: 10.1136/jcp.2009.066548
[7] Pirker R, Pereira JR, Szczesna A, et al.  Cetuximab plus chemotherapy in patientswith advanced non-small-cell lung cancer(FLEX): an open-label randomised phase Ⅲ trial[J]. Lancet, 2009, 373(9674): 1525-1531.   doi: 10.1016/S0140-6736(09)60569-9
[8] Yarden Y, Sliwkowski MX.  Untangling the Erb B signalling network[J]. Nat Rev Mol Cell Biol, 2001, 2(2): 127-137.   doi: 10.1038/35052073
[9] Linardou H, Dahabreh IJ, Bafaloukos D, et al.  Somatic EGFR muta-tions and efficacy of tyrosine kinase inhibitors in NSCLC[J]. Nat Rev Clin Oncol, 2009, 6(6): 352-366.
[10] Giaccone G, Johnson D, Scagliotti GV, et al.  Results of amultivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large Phase Ⅲ trials (INTACT 1 and 2)[J]. Proc Am Soc Clin Oncol, 2003, 22: 627-.
[11] Kanteti R, Yala S, Ferguson MK, et al.  MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance[J]. J Environ Pathol Toxicol Oncol, 2009, 28(2): 89-98.   doi: 10.1615/JEnvironPatholToxicolOncol.v28.i2.10
[12] Fredriksson A, Johnström P, Thorell JO, et al.  In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants[J]. Life Sci, 1999, 65(2): 165-174.   doi: 10.1016/S0024-3205(99)00233-7
[13] Rae JM, Lippman ME.  Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors[J]. Breast Cancer Res Treat, 2004, 83(2): 99-107.   doi: 10.1023/B:BREA.0000010702.10130.29
[14] Wang H, Yu JM, Yang GR, et al.  Further characterization of the epidermal growth factor receptor ligand 11C-PD153035[J]. Chin Med J (Eng1), 2007, 120(11): 960-964.   doi: 10.1097/00029330-200706010-00004
[15] Cole GW Jr, Alleva AM, Reddy RM, et al.  The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro[J]. J Thorac Cardiovasc Surg, 2005, 129(5): 1010-1017.
[16] Pal A, Glekas A, Doubrovin M, et al.  Molecular imaging of EGFR kinase activity in tumors with 124Ⅰ-labeled small molecular tracer and positron emission tomography[J]. Mol Imaging Biol, 2006, 8(5): 262-277.   doi: 10.1007/s11307-006-0049-0
[17] CaiW, Chen K, He L, et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody[J]. Eur J Nucl Med Mol Imaging, 2007, 34(6): 850-858.   doi: 10.1007/s00259-006-0361-6
[18] Abourbeh G, Dissoki S, Jacobson O, et al.  Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors[J]. Nucl Med Biol, 2007, 34(1): 55-70.
[19] Fredriksson A, Stone-Elander S.  PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo[J]. Methods Mol Med, 2003, 85: 279-294.